Treatment before surgery for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or III colorectal cancer (colon or rectal) that is confirmed by biopsy.
- Your tumor is in the rectum and located less than 10 cm from the anus, or it is colon cancer.
- You have not had any previous cancer treatment (such as chemotherapy, radiation, or immunotherapy).
- Your cancer has not spread to other parts of the body.
- Your blood counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (serplulimab, CAPOX, and bevacizumab) given before surgery to shrink locally advanced rectal cancer. The goal is to make the tumor easier to remove and potentially improve outcomes.
This trial tests a combination of drugs before surgery for locally advanced colorectal cancer. The goal is to see if this treatment shrinks the tumor and improves surgical outcomes.
This trial tests a combination of drugs given before surgery to shrink rectal cancer tumors and improve the chances of successful surgery. The drugs include an immunotherapy called serplulimab, chemotherapy (XELOX), and a targeted therapy called bevacizumab. This approach may help reduce the risk of the cancer coming back.
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.